Lake Street Maintains Accuray(ARAY.US) With Buy Rating, Maintains Target Price $6
Accuray Celebrates Opening of Genolier Innovation Hub in Switzerland, Initiation of CyberKnife S7 System Medical Professional Training
Genolier Innovation Hub, an Innovative Global Healthcare Center, Is Inaugurated Today in Switzerland
Accuray | 10-K: FY2024 Annual Report
Here's Why You Should Retain Accuray Stock in Your Portfolio Now
Lake Street Keeps Their Buy Rating on Accuray (ARAY)
Express News | Accuray Inc: Fourth Amendment Reduces Available Revolving Commitments Available Under Amended Credit Agreement to No More Than $20 Mln
Express News | Accuray Inc: On Sept 12, Entered Into Fourth Amendment to Credit Agreement
Gifu Prefectural General Medical Center Achieves Milestone With Treatment of the First Cancer Patients in Japan Using the Accuray Radixact System and VitalHold Solution
Express News | Accuray Inc - Sandeep Chalke Will Serve as Interim CEO During Winter's Absence
Accuray President and Chief Executive Officer Suzanne Winter to Take Temporary Medical Leave of Absence
Accuray Secures CE Mark For Accuray Helix, A CT-Guided Helical Radiotherapy System
Accuray Receives CE Mark for a New Helical Radiation Delivery System, Accuray Helix
Accuray's (NASDAQ:ARAY) Returns On Capital Not Reflecting Well On The Business
Accuray Incorporated's (NASDAQ:ARAY) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Accuray (NASDAQ:ARAY) May Have Issues Allocating Its Capital
Russell 2000 Set For Strongest Session In A Month As US Economy Defies Recession Fears: Small Cap Movers On Thursday
Express News | Accuray Shares up 39% After Co Raises Annual Rev Forecast
Lake Street Maintains Accuray(ARAY.US) With Buy Rating, Maintains Target Price $6
Lake Street analyst Brooks O'Neil maintains $Accuray(ARAY.US)$ with a buy rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 43.5% and a total
Accuray (ARAY) Q4 Earnings Lag Estimates, Gross Margin Shrinks